Order Article Reprints

Gay S, Raffa S, De’Luca di Pietralata A, Bauckneht M, Vera L, Miceli A, Albertelli M, Morbelli S, Giusti M, Ferone D. 2-[¹⁸F]FDG PET in the Management of Radioiodine Refractory Differentiated Thyroid Cancer in the Era of Thyrosin-Kinases Inhibitors: A Real-Life Retrospective Study. Diagnostics. 2022; 12(2):506. https://doi.org/10.3390/diagnostics12020506

Gay, Stefano, Stefano Raffa, Anna De’Luca di Pietralata, Matteo Bauckneht, Lara Vera, Alberto Miceli, Manuela Albertelli, Silvia Morbelli, Massimo Giusti, and Diego Ferone. 2022. "2-[¹⁸F]FDG PET in the Management of Radioiodine Refractory Differentiated Thyroid Cancer in the Era of Thyrosin-Kinases Inhibitors: A Real-Life Retrospective Study" Diagnostics 12, no. 2: 506. https://doi.org/10.3390/diagnostics12020506

Gay, S., Raffa, S., De’Luca di Pietralata, A., Bauckneht, M., Vera, L., Miceli, A., Albertelli, M., Morbelli, S., Giusti, M., & Ferone, D. (2022). 2-[¹⁸F]FDG PET in the Management of Radioiodine Refractory Differentiated Thyroid Cancer in the Era of Thyrosin-Kinases Inhibitors: A Real-Life Retrospective Study. Diagnostics, 12(2), 506. https://doi.org/10.3390/diagnostics12020506